UCSF's Quantitative Biosciences Institute Awarded $46 Million to Advance Groundbreaking Autism Research
–ARIA investment advances QBI's landmark Science study, accelerating the path from molecular discovery to new precision medicines for autism–
SAN FRANCISCO, August 27, 2026--The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) today announced it has been awarded a $46 million grant from Aligning Research to Impact Autism (ARIA) to expand its landmark research into the molecular mechanisms underlying autism spectrum disorder (ASD). The funding directly builds on a study published today in Science (DOI: 10.1126/science.ady4523) in which UCSF scientists at QBI and the Department of Psychiatry and Behavioral Sciences produced the largest-ever molecular interaction map of autism risk genes, revealing how hundreds of genetic mutations converge on a surprisingly small number of shared protein complexes, pointing toward a new generation of precision medicines.
The grant will support QBI's role as a key participant in ARIA's Protein-Protein Interactions Hub, one of six Research Hubs within ARIA's scientific ecosystem. The Hub brings together collaborative, multidisciplinary research teams from San Francisco, New York, Germany, and Switzerland to map disrupted protein complexes and to develop mechanism-based small molecule medicines capable of modulating them. The work is designed to move from the biological insights established in the Science study to therapeutic discovery that could one day benefit people with profound autism and others on the spectrum who seek additional support for daily life.
"Translating fundamental science into medicines that help patients requires not just the right ideas, but the sustained investment to follow those ideas all the way through," stated Nevan J. Krogan, Ph.D., professor at UCSF, director of QBI, and senior investigator at Gladstone Institutes. "ARIA's commitment does exactly that. It accelerates our ability to move from molecular insight to therapeutic impact, for autism and ultimately for many other diseases."
ARIA was established with a mission to drive scientific discovery and create more therapeutic opportunities for people with profound autism and people on the spectrum who seek additional support in order to improve daily life. By organizing its investments around focused scientific hubs integrated with a broad clinical-translational research infrastructure in the U.S., U.K., and Canada, ARIA aims to drive impact by fostering connections that might accelerate the development, testing, and scaling of the most promising therapies.